Next-generation Janus kinase inhibitors: Integrating synthetic innovation, structural biology, and computational design for precision drug discovery

Janus kinase (JAK) dysregulation plays a central role in the pathogenesis of inflammatory, autoimmune, and malignant disorders, making the JAK family an essential therapeutic target across multiple disease domains. Over the past two decades, the field has progressed from the identification of early JAK2 inhibitors to the approval of several first-generation agents, including ruxolitinib, tofacitinib, baricitinib, and fedratinib, which validated the clinical feasibility of JAK blockade. However, limitations related to safety, isoform selectivity, long-term tolerability, and off-target kinase interactions continue to restrict their broader application and highlight the need for next-generation molecules. In this review, we provide a comprehensive and strategic assessment of the molecular features underpinning JAK2 and JAK3 selectivity, including signaling features directly relevant to inhibitor design, mutational landscapes, and structural determinants such as the uniquely targetable Cys909 residue in JAK3. Although the JAK family comprises four kinases, this review intentionally focuses on JAK2 and JAK3, where structural divergence, disease relevance, and emerging selectivity strategies provide the strongest opportunities for next-generation precision inhibitor design. We integrate recent advances in synthetic chemistry, including hinge-binding optimization, heterocyclic diversification, multicomponent reactions, and scaffold-hopping strategies, with computational methodologies such as molecular docking, molecular dynamics simulations, QM/MM calculations, and machine-learning-based predictive modelling. Together, these multidisciplinary approaches have accelerated hit discovery, refined selectivity, and improved the pharmacokinetic and safety profiles of emerging JAK inhibitors. By consolidating progress across medicinal chemistry, structural biology, and computational design, this review outlines key opportunities and remaining challenges in developing next-generation JAK inhibitors with enhanced precision and therapeutic value for oncology, immunology, and chronic inflammatory diseases.